The GOLIM4 Knockout NCI-H1975 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function investigation of the GOLIM4 gene. This product comprises a heterogeneous pool of NCI-H1975 cells with targeted gene disruption, enabling functional studies without clonal selection. The polyclonal format captures a wide range of genetic alterations, offering a robust model for examining GOLIM4-dependent processes in cancer cell biology.
The NCI-H1975 cell line is a human lung adenocarcinoma epithelial model derived from the pleural effusion of a female patient with non-small cell lung cancer. These cells carry activating EGFR mutations, specifically L858R and T790M, which are associated with resistance to first-generation tyrosine kinase inhibitors while retaining sensitivity to third-generation inhibitors. Consequently, NCI-H1975 is widely employed to study mechanisms of acquired drug resistance and EGFR-driven tumor progression.
GOLIM4 encodes a cis-Golgi integral membrane protein essential for glycoprotein trafficking, glycosylation, and sorting. It directly interacts with key Golgi machinery, including ARF1, the COPI coatomer complex, Golgin-97, and Rab GTPases, and is regulated by EGFR signaling and Golgi stress. Through mediating proper glycosylation, GOLIM4 influences the cell surface expression and functionality of receptors such as EGFR, as well as acting as a cellular receptor for certain parvoviruses and adenoviruses, linking Golgi function to viral entry.
Disruption of GOLIM4 in the NCI-H1975 background impairs cis-Golgi glycoprotein processing, leading to aberrant glycosylation of cell surface receptors including EGFR. This alteration can perturb EGFR stability and downstream signaling cascades, potentially affecting drug sensitivity and metastatic properties. Moreover, changes in glycosylation patterns may impact viral tropism and intracellular routing. This engineered model therefore provides a unique system to dissect how Golgi-mediated post-translational modifications intersect with oncogenic signaling and viral susceptibility in a clinically relevant NSCLC context.
These polyclonal knockout cells are ideally suited for a range of research applications, including the study of Golgi-mediated glycosylation, EGFR trafficking and signaling dynamics, and resistance mechanisms to targeted therapies. Researchers can employ Western blotting to assess glycoprotein processing defects, immunofluorescence to visualize Golgi morphology and protein localization, flow cytometry to quantify surface EGFR expression, and migration/invasion assays to evaluate metastatic potential. Phospho-EGFR analysis and viral infectivity assays further enable delineation of signaling networks and host?Cvirus interactions. For further details, please contact Ascent Research.
